XFOR Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -2776.92% compared to X4 Pharmaceuticals's net margin of 32.59%. X4 Pharmaceuticals's return on equity of -82% beat Eli Lilly and's return on equity of 80.24%.

X4 Pharmaceuticals has a consensus price target of $2.50, signalling upside risk potential of 1215.79%. On the other hand Eli Lilly and has an analysts' consensus of $1,008.64 which suggests that it could grow by 14.03%. Given that X4 Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe X4 Pharmaceuticals is more attractive than Eli Lilly and.

X4 Pharmaceuticals has a beta of 0.579, which suggesting that the stock is 42.116% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

X4 Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.61% to investors and pays a quarterly dividend of $1.50 per share. X4 Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

X4 Pharmaceuticals quarterly revenues are $1.4M, which are smaller than Eli Lilly and quarterly revenues of $13.5B. X4 Pharmaceuticals's net income of -$39.8M is lower than Eli Lilly and's net income of $4.4B. Notably, X4 Pharmaceuticals's price-to-earnings ratio is 7.78x while Eli Lilly and's PE ratio is 75.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals is -- versus 17.75x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -2776.92% compared to X4 Pharmaceuticals's net margin of -49.65%. X4 Pharmaceuticals's return on equity of -82% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

X4 Pharmaceuticals has a consensus price target of $2.50, signalling upside risk potential of 1215.79%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 46.55%. Given that X4 Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe X4 Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

X4 Pharmaceuticals has a beta of 0.579, which suggesting that the stock is 42.116% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

X4 Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

X4 Pharmaceuticals quarterly revenues are $1.4M, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. X4 Pharmaceuticals's net income of -$39.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, X4 Pharmaceuticals's price-to-earnings ratio is 7.78x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

PAVmed has a net margin of -2776.92% compared to X4 Pharmaceuticals's net margin of -1105.92%. X4 Pharmaceuticals's return on equity of -82% beat PAVmed's return on equity of --.

X4 Pharmaceuticals has a consensus price target of $2.50, signalling upside risk potential of 1215.79%. On the other hand PAVmed has an analysts' consensus of $11.75 which suggests that it could grow by 1446.05%. Given that PAVmed has higher upside potential than X4 Pharmaceuticals, analysts believe PAVmed is more attractive than X4 Pharmaceuticals.

X4 Pharmaceuticals has a beta of 0.579, which suggesting that the stock is 42.116% less volatile than S&P 500. In comparison PAVmed has a beta of 1.133, suggesting its more volatile than the S&P 500 by 13.28%.

X4 Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PAVmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals pays -- of its earnings as a dividend. PAVmed pays out -- of its earnings as a dividend.

X4 Pharmaceuticals quarterly revenues are $1.4M, which are larger than PAVmed quarterly revenues of $10K. X4 Pharmaceuticals's net income of -$39.8M is lower than PAVmed's net income of $1.4M. Notably, X4 Pharmaceuticals's price-to-earnings ratio is 7.78x while PAVmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals is -- versus 4.66x for PAVmed. Usually stocks with elevated PS ratios are considered overvalued.

Prestige Consumer Healthcare has a net margin of -2776.92% compared to X4 Pharmaceuticals's net margin of 21.02%. X4 Pharmaceuticals's return on equity of -82% beat Prestige Consumer Healthcare's return on equity of 12.65%.

X4 Pharmaceuticals has a consensus price target of $2.50, signalling upside risk potential of 1215.79%. On the other hand Prestige Consumer Healthcare has an analysts' consensus of $86.67 which suggests that it could grow by 7.61%. Given that X4 Pharmaceuticals has higher upside potential than Prestige Consumer Healthcare, analysts believe X4 Pharmaceuticals is more attractive than Prestige Consumer Healthcare.

X4 Pharmaceuticals has a beta of 0.579, which suggesting that the stock is 42.116% less volatile than S&P 500. In comparison Prestige Consumer Healthcare has a beta of 0.470, suggesting its less volatile than the S&P 500 by 53.023%.

X4 Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prestige Consumer Healthcare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals pays -- of its earnings as a dividend. Prestige Consumer Healthcare pays out -- of its earnings as a dividend.

X4 Pharmaceuticals quarterly revenues are $1.4M, which are smaller than Prestige Consumer Healthcare quarterly revenues of $290.3M. X4 Pharmaceuticals's net income of -$39.8M is lower than Prestige Consumer Healthcare's net income of $61M. Notably, X4 Pharmaceuticals's price-to-earnings ratio is 7.78x while Prestige Consumer Healthcare's PE ratio is 18.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals is -- versus 3.61x for Prestige Consumer Healthcare. Usually stocks with elevated PS ratios are considered overvalued.